Your browser doesn't support javascript.
loading
Role of the IGF-1/PI3K pathway and the molecular mechanism of Fuzhenghuayu therapy in a spontaneous recovery rat model of liver fibrosis / 中华肝脏病杂志
Chinese Journal of Hepatology ; (12): 674-678, 2013.
Article in Chinese | WPRIM | ID: wpr-278021
ABSTRACT
<p><b>OBJECTIVE</b>To determine the role of IGF-1/PI3K pathway and investigate the molecular mechanism of Fuzhenghuayu (FZHY) therapy in a spontaneous recovery rat model of liver fibrosis.</p><p><b>METHODS</b>The liver fibrosis model was induced in male Wistar rats by administering 8 weeks of twice weekly CCL4 intraperitoneal injections without (untreated model) or with once daily FZHY (treated model). Normal, untreated rats served as the control group. At weeks 4, 6 and 8 (fibrosis) and 10, 12 and 14 (spontaneous recovery) after modeling initiation, effects on protein (a-SMA, IGF-1, PI3K) and mRNA (IGF-1, PI3K) expression levels were evaluated by immunohistochemistry and RT-PCR, respectively. Serum markers of liver function (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) and liver cell damage (alkaline hydrolysis, HYP) were measured. Histology was performed to assess the degree of inflammation and fibrosis (Ishak scoring system).</p><p><b>RESULTS</b>In the untreated model group, progression of liver fibrosis (weeks 4, 6 and 8) was accompanied by gradual increases in inflammation, necrosis, serum ALT and AST, and hepatic expression of a-SMA protein and IGF-1 and PI3K protein and mRNA; however, during the spontaneous recovery period (weeks 10, 12 and 14) the IGF-1 and PI3K protein and mRNA levels rapidly decreased and the HYP level, Ishak score, and a-SMA hepatic expression also decreased. The FZHY-treated model group showed significantly lower fibrosis-related up-regulation of IGF-1 and PI3K protein and mRNA expression, HYP level, Ishak score, and a-SMA hepatic expression at each time point (vs. untreated model group).</p><p><b>CONCLUSION</b>The IGF-1/PI3K pathway may contribute to progression of liver fibrosis. The mechanism by which FZHY prevents liver fibrosis in a rat model may involve blocking of the IGF/PI3K pathway and inhibiting HSC activation.</p>
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Pathology / Pharmacology / Insulin-Like Growth Factor I / Drugs, Chinese Herbal / Signal Transduction / Rats, Wistar / Phosphatidylinositol 3-Kinases / Liver / Liver Cirrhosis, Experimental / Metabolism Type of study: Prognostic study Limits: Animals Language: Chinese Journal: Chinese Journal of Hepatology Year: 2013 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Pathology / Pharmacology / Insulin-Like Growth Factor I / Drugs, Chinese Herbal / Signal Transduction / Rats, Wistar / Phosphatidylinositol 3-Kinases / Liver / Liver Cirrhosis, Experimental / Metabolism Type of study: Prognostic study Limits: Animals Language: Chinese Journal: Chinese Journal of Hepatology Year: 2013 Type: Article